As part of the presentation Dr. Silberman will discuss the Company's drug candidate, TPI 287. TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) ...

Study to evaluate Berubicin for the treatment of newly diagnosed and relapsed/refractory primary central nervous system lymphoma (PCNSL) or non-Hodgkin's lymphoma with central nervous system ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has CNS Pharmaceuticals, Inc. (CNSP) been one of those stocks ...

In person presentation today, Thursday, June 5 th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) As part of the presentation Dr ...

In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / ...